Incyte's Opzelura cream has become the first medical treatment approved to re-pigment the skin of people with vitiligo in the US, adding to its current use in atopic dermatitis.
This article is sponsored by Incyte. Lisa was compensated for her time participating in the interview. For Lisa, life with ...
Incyte could be a few month away from a second FDA approval for its Opzelura cream that would make it the first medical treatment to re-pigment the skin of people with vitiligo. The FDA has kicked ...
Another JAK inhibitor -- ruxolitinib -- is already approved as a topical formulation (Opzelura) to treat vitiligo. But the indication is only for vitiligo affecting the face and no more than 10% ...
vitiligo at 1 year Safety data for ruxolitinib cream (Opzelura, Incyte), a Janus kinase inhibitor, in the first year after its approval has shown that the drug is generally well tolerated for the ...
INCY has delivered a good performance in the past year on positive data readouts and encouraging pipeline progress. We believe there is room for further growth at current levels.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results